Sphera Funds Management’s AnaptysBio ANAB Stock Holding History

Sphera Funds Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-70,000	Closed	-$5.11M	–	90
2019 Q1	$5.11M	Buy	+70,000	New	+$4.83M	0.47%	48
2018 Q1	–	Sell	-35,000	Closed	-$3.52M	–	110
2017 Q4	$3.52M	Sell	35,000 -45,000	-56%	-$3.31M	0.41%	58
2017 Q3	$2.8M	Buy	+80,000	New	+$2.16M	0.4%	63
2017 Q2	–	Sell	-25,500	Closed	-$708K	–	130
2017 Q1	$708K	Buy	+25,500	New	+$594K	0.14%	99

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's ANAB Position: Q2 2019 in Review

Sphera Funds Management sold out of AnaptysBio (ANAB) in Q2 2019, closing a stake of 70,000 shares — an estimated $5.11M sold.

Sphera Funds Management first reported a position in ANAB in Q1 2017 and held it in 4 quarters. The position peaked at $5.11M in Q1 2019. 127 funds tracked by Wall St. Rank hold ANAB as of Q2 2019.

Sphera Funds Management reported no remaining AnaptysBio position as of Q2 2019 after selling out during the quarter.
Sphera Funds Management sold 70,000 AnaptysBio shares in Q2 2019, an estimated $5.11M.
Sphera Funds Management first reported a position in AnaptysBio in Q1 2017 and held it in 4 quarters.
Sphera Funds Management's AnaptysBio position peaked at $5.11M in Q1 2019.
127 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2019.

Based on Sphera Funds Management's 13F filing for Q2 2019, filed 14 Aug 2019.